By SPC News Staff
The FDA approved deucravacitinib (Sotyktu, Bristol Myers Squibb) to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The approval is based on results from the pivotal phase 3 POETYK PSO-1 and POETYK PSO-2 multinational, multicenter, randomized, double-blind clinical trials. The drug was compared with both placebo and active comparator arms. Once-daily deucravacitinib 6 mg was compared with placebo and